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Translational Oncology Vol. 12, No. 2, 2019 miR-224 in Colorectal Carcinogenesis Fassan et al. 283the presence of a DNA mismatch repair deficiency. miR-224 targets caspase-3 and caspase-7 in colorectal cancer,
and this inverse relation was already evident from the earliest phases of transformation in intestinal mucosa. The
miR-224/caspases axis may represent an interesting field of study for innovative biomarkers/therapeutics for
BRAF-mutated/DNA mismatch repair-deficient tumors.
Translational Oncology (2019) 12, 282–291te
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or many years, sporadic colorectal cancer (CRC) has been
nsidered to be a homogeneous condition developing within the
ntext of the adenoma-carcinoma phenotypic sequence driven by
e accumulation in genetic alterations of CRC key genes such as
PC, KRAS, and TP53 [1]. However, comprehensive genomic
ofiling studies pinpointed the existence of multiple phenotypic and
olecular CRC cascades with specific clinical and therapeutic
plications. This heterogeneity includes colon mucosa transforma-
on through the serrated pathway, alterations in the BRAF gene, and
e presence of microsatellite instability (MSI) [1–3]. Another
portant colon mucosa cancerization field is represented by
flammatory bowel diseases (IBD), and both Crohn's disease
D) and ulcerative colitis (UC) patients carry a significantly
creased risk of developing CRC [4].
miRs aberrant expression is common in CRC and has been
sociated to cancer progression and clinical outcome [5,6]. Among
e others, miR-224 has emerged as a driver oncomiR involved in
lorectal carcinogenesis [7–17] and has been demonstrated to be a
ognostic marker for survival of patients with CRC [7,12]. When
alyzed in the context of the CRC molecular landscape, miR-224
s been shown to be significantly downregulated in BRAF mutated
mors and in presence of MSI [8,12].
Several cancer-associated genes, such as SMAD4 [12,14,18,19]
d p21 [13], have been validated to be directly targeted by miR-224
the colorectal setting. In other cancers, miR-224 has been
scribed to be a negative regulator of RASSF8 [20–22], HOXD10
3,24], and caspases [25].
Here, we tested miR-224 expression and dysregulation in a large
enotypical and molecular characterized series of preinvasive and
vasive colorectal lesions, and we provide evidence supporting a driver
le for miR-224 in the neoplastic progression of CRC. We also
monstrated that miR-224 is targeting caspases expression in CRC.
aterials and Methods
thical Approvals
Investigation has been conducted in accordance to the Declaration
Helsinki and according to national and international guidelines.
raffin-embedded tissues considered in this study were retrospec-
vely collected and analyzed following approval of the ethical
mmittees from the files of the 1) Ohio State University Pathology
rchive; 2) Department of Pathology, University of Ferrara; and 3)
rgical Pathology Unit, University of Padua.
issue Samples
Original slides (4-6 μm thick) obtained from archival paraffin-
bedded tissue samples (H&E) were reassessed by expert gastroin-stinal pathologists. In all cases, the histology assessment of IEN and
RC was done according to the current histology criteria [26–28].
Four hundred eleven tissue samples from a total of 377 patients
ere tested in the study:) Sporadic carcinogenesis. A series of 60 endoscopy biopsy samples
was obtained from patients with different types of left-side sporadic
colic lesions: 20 tubular adenomas with low-grade intraepithelial
neoplasia (LG-IEN, formerly known as LG-dysplasia), 20 tubular
adenomas with high-grade IEN (HG-IEN), and 20 well-
differentiated (G1) pT1/pT2 CRCs. Another 20 normal colonic
mucosa biopsy samples were obtained frompatients who underwent
colonoscopy for irritable bowel syndrome. No sample was obtained
from cases of familial adenomatous polyposis syndrome.
) IBD-related carcinogenesis. A total of 175 IBD-related samples (98
from UC patients and 77 from CD patients) were obtained from
colectomy samples performed for histologically proven dysplastic/
invasive lesions. The assessment of IBD acute inflammation versus
nonactive inflammation was based on microscopic criteria, activity
being defined as the presence of neutrophils or unequivocal damage
of the surface and crypt epithelium typically in conjunction with
neutrophils [27,29]. For UC, a total of inactive disease (n = 50),
IEN (n = 26; both low and high grade), and CRC (n = 22)
specimens were considered. The 77 CD-related specimens included
inactive disease (n = 50), IEN (n = 13; both low and high grade),
and CRC (n = 14) specimens.
) A further series of 156 colectomy specimens was considered
according to pathological and molecular features of the tumors. In
17 stage IV cases, matched samples of normal colorectal mucosa
(N3 cm far from CRC), primary CRC, and synchronous liver
metastasis were selected, for a total of 51 samples. Another 105
CRC cases were retrospectively selected according their molecular
profiling, as assessed for clinical purposes by Sequenom MassArray
sequencing (for the purposes of the study, only themutational status
of KRAS exons 2-4, NRAS exons 2-4, and BRAF exon 15 was
considered; Diatech Pharmacogenetics, Jesi, Italy) and by immu-
nohistochemical evaluation of DNA mismatch repair (MMR)
proteins (MSH2, MSH6, MLH1, PMS2; Dako, Carpinteria, CA)
to assess MMR proficiency (MMRp) or deficiency (MMRd). In
case ofMMRd, cases were evaluated formicrosatellite status (Titano
kit; Diatech Pharmacogenetics), and in all the considered MMRd
cases, microsatellite instability (MSI) was confirmed. These 105
CRCs were classified as: KRAS/NRAS/BRAF wild type and
mismatch repair proficient (MMRp) (n = 25), KRAS exon 2G12-
mutated (n = 25), KRAS exon 2G13-mutated (n = 25), BRAF
exon 15 V600E-mutated and mismatch repair deficient (MMRd;
which usually correspond to a MSI phenotype) (n = 20), BRAF
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Figure 1. miR-224 is significantly upregulated in sporadic and IBD-
related colorectal carcinogenesis. (A) A significant miR-224 upregula-
tion was observed by qRT-PCR in LG-IEN (P = .033), in HG-IEN
(P b .001), and in early-stage CRCs (P b .001) in comparison to normal
colon mucosa. Also, HG-IEN lesions and CRCs showed a significantly
higher miR-224 expression in comparison to LG-IEN adenomas (both
P b .001). (B) Representative ISH analysis pictures showing a
significant miR-224 overexpression in HG lesions in comparison to
LG adenomas (ORIGINALmagnifications 20×, scale bars 100 μm) and
the relative expression as assessed by image software analysis. (C-D)
miR-224 expression (qRT-PCR)was also investigated in a large series of
IBD-related IEN (n = 39) and CRC (n = 36) lesions. In both ulcerative
colitis (UC; C) and Crohn's disease (CD; D), miR-224 levels were
significantly upregulated between inactive IBD disease or IEN and full-
blownCRC (UC,P b .001 andP = .006, respectively; CD,P b .001 and
P = .010, respectively). Although not significant, miR-224 expression
was higher in IEN samples in comparison to inactive disease.
284 miR-224 in Colorectal Carcinogenesis Fassan et al. Translational Oncology Vol. 12, No. 2, 2019exon 15 V600E-mutated and MMRp (n = 5), and KRAS/NRAS/
BRAF wild type and MMRd (n = 5). The 25 KRAS/NRAS/BRAF
wild-type and MMRp samples were selected as age- and stage-
matched to the MMRd tumors series.
utational Profiling
Screening for mutations was performed on a Sequenom
assARRAY platform by applying the Myriapod Colon status
nel (Diatech Pharmacogenetics, Jesi, Italy). Details on targeted
tspots of the commercial panel are at http://www.diatechpharma-
genetics.com. In each case, DNA was prepared after enrichment for
oplastic cellularity to at least 60% using manual microdissection of
consecutive 4-μm FFPE sections and purified using the QIAamp
NA FFPE Tissue Kit (Qiagen; Milan, Italy). In a random set of 20
mples, mutational profiling was validated by Sanger sequencing.
iR-224 In Situ Hybridization (ISH) and Immunohistochemical
HC) Analyses
Fifty-five primary CRC surgical samples (25 KRAS mutated, 5 BRAF
utated, 10 MMRd) were processed using the Galileo CK3500 Arrayer
ww.isenet.it), a semiautomatic and computer-assisted tissuemicroarray
atform, as previously described [30,31]. Three tissue cores (1 mm in
ameter) were obtained from each considered lesion.
Locked nucleic acid (LNA) probes with complementarity to miR-
4 were labeled with 5′-biotin and synthesized using Exiqon
edbaek, Denmark). Tissue sections were digested with ISH protease
(Ventana Medical Systems, Milan, Italy), and ISH was performed as
eviously described [25,32], with minor modifications. Positive (U6;
xiqon) and negative scrambled LNA probes were used as controls
upplementary Figure 1). Only cytoplasmic miR-224 intensity was
tained for scoring purposes.
Protein/microRNA co-expression analysis was carried out as
eviously described withminor modifications [25]. After ISH staining,
e used theBenchmark LT automated system fromLeicaMicrosystems
ondmax (Leica, Wetzlar, Germany) according to the manufacturer's
ecifications to perform the immunohistochemistry for CASP3 or
ASP7 (Santa Cruz Biotechnology, Inc.; Dallas, TX). The expression
CASP3 or CASP7 was cytoplasmic and nuclear. Color-relative
aining intensities were evaluated by 1) semiquantitative evaluation
nsidering a three-tier scale according to the intensity of the reaction
= negative; 1+ = faint/moderate staining; 2+ strong and diffuse
aining) and 2) ImageJ software evaluation.
DNA mismatch repair machinery deficient tumors (MMRd) were
fined in the absence of nuclear immunostaining for one of the
uples MLH1/PMS2 or MSH2/MSH6 (Dako, Carpinteria, CA) in
mor cells, as assessed in the colorectal setting [33].
everse Transcription and Quantitative Real-Time PCR
Total RNA was extracted using the RecoverAll kit (Ambion, Austin,
X). The NCodeTMmiRNA qRT-PCRmethod (Invitrogen, Carlsbad,
A) was applied to detect and quantifymature hsa-miR-224 according to
e manufacturer's instructions using an ABI Prism 7900HT Sequence
etection System (Applied Biosystems, Foster City, CA). Normalization
as performed with the small nuclear RNA U6B. All reactions were run
duplicate, including no-template controls.
lasmid Construction, Cell Lines, and Reagents
All the human CRC-derived cell lines used in this study were
rchased from the American Type Culture Collection (ATCC,
anassas, VA). RKO and HCT116 cells were regularly maintained
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Translational Oncology Vol. 12, No. 2, 2019 miR-224 in Colorectal Carcinogenesis Fassan et al. 285McCoy-5A media (Life Technologies, Carlsbad, CA) containing
% fetal bovine serum (Life Technologies) and 1% streptomycin-
nicillin (Life Technologies) at 37°C in a CO2 incubator (5% CO2,
0% H2O).
For transfection experiments, the human miR-224 precursor
iRNA and the negative control were purchased from Thermo
sher Scientific (Waltham, MA). The experiments were run in
iplicates.
For Western blot analysis, antibody against CASP7 was purchased
om Cell Signaling (Danvers, MA), whereas anti-vinculin antibody
as from Sigma-Aldrich (Saint Louis, MO).
rray Database Meta-Analysis
The TCGA (https://cancergenome.nih.gov/) and the Oncomine
ww.oncomine.org) databases and gene microarray analysis tools
ere explored (15 June 2016) to assess miR-224 and caspases
pression in colorectal cancer samples. Oncomine algorithms, which
able multiple comparisons among different studies, were used for
e statistical analysis of the differences in mRNA expression between
e aforementioned comparisons.
atistical Analysis
Differences between groups were tested by applying the unpaired/
ired t test, ordinary one-way ANOVA with the Greenhouse-Geisser
rrection, and Fisher’s exact test, as appropriate. P values b.05 were
nsidered significant. The statistical analysis was performed using
ATA software (Stata Corporation, College Station, TX).
esults
iR-224 Is Significantly Upregulated in Sporadic and
D-Related Colorectal Carcinogenesis
To extend previous findings onmiR-224 expression in CRC [7–17],
iR-224 expression (qRT-PCR) was investigated in 80 endoscopy
opsy samples representative of 20 normal colon mucosa, 40 sporadic
bular adenomas, and 20 early-stage CRCs. A significant miR-224
regulation was observed in LG-IEN (P = .033), in HG-IEN
b .001), and in CRC (P b .001) in comparison to normal mucosa,
d among LG-IEN and HG-IEN lesions (P b .001), LG-IEN and
RC (P b .001) (Figure 1A). Overall, miR-224 expression increased
ogressively and significantly along with the adenoma-carcinoma
quence (ANOVA, P b .001).
To further confirm miR-224 overexpression according to IEN
ading, miR-224 ISH analysis was performed in 5 normal colon
ucosa, 5 LG-IEN, and 5 HG-IEN samples. The dysplastic samples
owed a weak to moderate granular blue miR-224 cytoplasmic staining
neoplastic epithelia. Also, lymphocytes and plasma cells showed a faint
toplasmic staining. The analysis of the relative miRNA expression as
quired by Image J software demonstrated a higher miR-224
erexpression in dysplastic lesions in comparison to normal mucosa
= .012 for LG-IEN and P = .002 for HG-IEN) and in HG-IEN
mpared to LG-IEN lesions (P = .041) (Figure 1B).
We also investigated miR-224 expression in two series of endoscopy
opsy samples obtained from IBD patients. Of note, these series
cluded a significant number of IBD-related IEN (n = 39) and CRC
= 36) samples. In both UC and CD (Figure 1C) samples, a
gnificant miR-224 upregulation was observed in full-blown CRC
mpared to the inactive IBD disease or IEN. Even if the difference was
t statistically significant, miR-224 expression was higher in IEN
mples in comparison to inactive disease.iR-224 Dysregulation in Advanced CRCs Is Dependent on
e Molecular Landscape of the Lesion
The role ofmiR-224duringCRCprogression is controversial [9,12,15].
owever, most studies have demonstrated that miR-224 overexpression
omotes CRC metastasis and is an important prognostic marker in
RC patients. To further test this hypothesis, we investigated miR-224
pression by qRT-PCR in a series of 17 stage IV CRCs (Figure 2A). A
nificant overexpression of miR-224 was observed in both primary
RCs (P b .001) and liver metastases (P b .001) compared to matched
rmal colon mucosa. Metastatic samples also showed a significantly
gher miR-224 expression in comparison to primary tumors (P b .001).
verall,miR-224 expression increased progressively and significantly along
ith CRC metastatic sequence (P b .001).
miR-224 expression was also investigated by ISH in five cases of
age IV CRCs. A consistently significant overexpression was observed
paired primary tumors and CRC liver metastasis in comparison to
rmal colon mucosa in all the tested samples (Figure 2B). Normal
locytes showed a negative or faint cytoplasmic staining.
A retrospective series of 105 molecularly characterized CRCs was
lected according to their KRAS/NRAS/BRAF status and the expression
four mismatch repair proteins to test miR-224 dysregulation according
theCRCmolecular landscape.No significant differences were observed
ong CRCs stratified according to KRAS status (Figure 2C), whereas a
nificant downregulation was observed in BRAF-mutated tumors in
mparison to wild-type (P = .013) and KRAS-mutated (P b .001)
mples. Further supporting these observations, in two cases per group,
iR-224 ISH analysis was performed and revealed a moderate to strong
toplasmic expression in all wild-type and KRAS-mutated tested
mples; the two BRAF-mutated tumors showed a moderate expression
the miR-224. Moreover, as previously observed [12], miR-224 was
nificantly overexpressed in a small series of MMRp tumors in
mparison to an age- and stage-matched MMRd tumors group
b .001; Figure 2D).
In keeping with tissue data, analysis of miR-224 expression in 7
RC cell lines demonstrated that 3 out of 4 MSI cell lines were
aracterized by a low miR-224 expression (Figure 3A).
aspases 3 and 7 as miR-224 Targets in Colorectal Carcinogenesis
We have previously reported that miR-224 is implicated in lung
ncer pathogenesis through targeting caspase-3 and caspase-7. Our
ciferase reporter assays also confirmed miR-224 directly binding to
e 3’UTR of caspase3 and caspase-7 [25]. Among the seven CRC cell
es, we selected the two characterized by the lowest miR-224
pression (i.e., RKO and HCT116) to overexpress miR-224. We
ansiently transduced these two cell lines with miR-224 precursor and
nfirmed miR-224 overexpression by qRT-PCR (Figure 3B). The
erexpression resulted in a significant reduction in pro-caspase-7
pression, as assessed by Western blot analysis (92.2% reduction for
KO cells and 87.9% reduction for HCT116), whereas no significant
teration was observed in pro-caspase-3.
The correlation between miR-224 and its target proteins (i.e., caspase-
and caspase-7) was further evaluated by miR-224 ISH and caspase
munohistochemical analyses in a series of 10 normal colon mucosae, 5
bular adenomas with low-grade dysplasia, and 55 CRCs.
Both caspases showed a moderate/strong cytoplasmic and nuclear
munoreaction in normal crypts, with a decreased expression within
and's neck and superficial epithelial layer (Figure 4A and Supplementary
gure 2). CRCs showed a negative to moderate caspases expression. A
nificant inverse correlation between miR-224 and caspases expression
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286 miR-224 in Colorectal Carcinogenesis Fassan et al. Translational Oncology Vol. 12, No. 2, 2019as observed in the series of 55 CRCs (Figure 4,B andC). Of note, 7 out
the 10 MSI CRCs showed a negative to faint miR-224 expression,
hich was associated to a moderate caspases expression.
This inverse relationship (i.e., lower the caspases, higher the miR-
4) was also observed in the five tubular adenomas, supporting an early
cogenic role for miR-224. The dysplastic glands showed a significant
wnregulation in caspase expression concurrent to a miR-224
erexpression (Supplementary Figure 3).To further support these data, we explored the TCGA and the
ncomine databases (Figure 5). In the TCGA series, miR-224 resulted
being significantly upregulated in CRCs in comparison to normal
mples (P = .001688), whereas both caspases were significantly
wnregulated (caspase-3, P = 6.67e-08; caspase-7, P b 2.2e-16)
igure 5A). Caspase-3 expression was significantly downregulated in
RC in comparison to normal mucosa in 4 out of 6 Oncomine
posited studies (a total of 269 CRCs and 107 normal samples
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Figure 3. miR-224 is downregulated in MSI CRC-derived cancer cell line, and its overexpression targets caspase-7 expression. (A) We
tested miR-224 expression in seven CRC-derived cell lines and observed that three out of four MSI cell lines were characterized by a
significantly lowmiR-224 expression (the molecular profiling of the single cell lines is also shown). (B) miR-224 overexpression in RKO and
HCT116 corresponded to a significant reduction in procaspase-7 expression, as assessed by Western blot analysis (92.2% reduction for
RKO cells and 87.9% reduction for HCT116).
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wnregulated in 7 out of 8 studies (a total of 415 CRCs and 186
rmal samples analyzed; P = 1.02e-5; Figure 5C).
iscussion
espite recent improvements in therapymainly due to the introduction
predictive biomarkers into clinical practice, CRC still remains amajor
alth burden with significant morbidity andmortality worldwide [34].
Among the different classes of cancer biomarkers,miRs have emerged
novel noninvasive tools for diagnostic, predictive, and prognostic
plications in tissues and biofluids [17] and as having a potential role as
erapeutics [35].
miR-224 has emerged as a potential driver of CRC acting as an
comiR; however, some contrasting data related to its expression
ve been reported [9,12,15].
Here we demonstrated an early upregulation of miR-224 in both
oradic and IBD-related carcinogenetic process. In the adenoma-
rcinoma pathway, both low-grade and high-grade intraepithelial
sions (i.e., dysplasia) were characterized by miR-224 overexpression,ure 2. miR-224 is significantly upregulated in metastatic disease and is downregulated in MMRd tumors. (A) miR-224 expression was
luated by qRT-PCR in matched normal, primary CRC and synchronous liver metastasis obtained from a series of 17 stage IV CRCs. A
nificant overexpression of miR-224 was observed in primary CRCs in comparison to normal colon mucosa (P b .001) and CRC liver
tastases in comparison to primary CRCs (P b .001) compared to normal colon mucosa. (B) ISH analysis further confirmed qRT-PCR data,
h a significant mIR-224 overexpression in paired primary tumors and CRC livermetastasis in comparison to normal colonmucosa. Note in
metastasis picture, the miR-224 negative hepatic parenchyma in comparison to the miR-224 positive metastatic lesion (original
gnifications 10× and 40×, scale bars 100 μm). On the right is the relative value as assessed by image software analysis, which confirmed
-PCR data. (C) No significant differences in miR-224 expression were observed among CRCs stratified according to KRAS status, as
firmed by both qRT-PCR and ISH analyses. BRAF-mutated tumors showed a lower miR-224 expression in comparison to wild-type and
S-mutated tumors (P = .013 and P b .001, respectively). On the bottom of the figure is the representation of the results of Sanger
uencing. (D) MMRp tumors showed a significantly higher miR-224 expression in comparison to an age- and stage-matched MMRd
ors series (P b .001). Representative images of mismatch repair protein immunohistochemical status are also shown.ig
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mhich was demonstrated by both in vitro and in situ studies. On the
her hand, in the context of IBD, dysplastic lesions did not show a
gnificant overexpression in comparison to colon mucosa with
active disease, which support an important oncogenic role of
flamed mucosa in tumor initiation via early dysregulation of several
rcinogenetic pathways. Thus, our data support the use of miR-224
pression as an early biomarker of colon mucosa transformation in
e sporadic setting; however, miR-224 has no significant diagnostic
pact in discriminating dysplastic epithelia from surrounding
ucosa in IBD patients.
We further demonstrated that miR-224 is also involved in the
quisition of the metastatic phenotype. It has to be underlined that
e examined matched samples obtained from 17 stage IV CRC
tients, and miR-224 expression was always higher in metastatic
posits in comparison to the corresponding primary tumor. In their
minal article, Yuan and colleagues showed an antimetastatic effect
miR-224 on CRC-derived cancer cell lines [15]; however, this
uld have been related to the molecular characteristics of the cell
es adopted for their in vivo experiments.
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Figure 4. CRCs are characterized by a significant miR-224/caspases inverse correlation. (A) Representative images of miR-224 ISH and
caspase-3 and caspase-7 immunohistochemical analyses in a series of normal colic mucosa and CRC samples. (original magnifications
10×, scale bars 200 μm). (B) The analysis of 55 primary CRCs samples demonstrated a significant inverse correlation between miR-224
and caspases expression. (C) Two representative cases in which there was a significant inverse relationship between the expression of
the miR-224 and of the two caspases.
288 miR-224 in Colorectal Carcinogenesis Fassan et al. Translational Oncology Vol. 12, No. 2, 2019Another important observation gathered by the analysis of our samples
the validation of previous results published by Ling and colleagues [12]
the different miR-224 expression profiles depending on themolecular
ndscape of the tumors. This concordance corroborates the quality of
e presented data. In our series, we did not observe any difference in
iR-224 expression according to KRAS status, which is in contrast to
mankwatia and colleagues [8] but in line with the larger series of Ling
2]. Moreover, we observed a significant miR-224 downregulation
ong tumors characterized by a BRAFV600E mutation and by the
MRd phenotype. Because most of the BRAFV600E-mutated samples
ere also MMRd, it is difficult to understand the genetic driver of this
fference, and larger series of samples should be investigated to clarify
is point.
As previously demonstrated in lung cancer, miR-224 targets
spase-3 and caspase-7 also in CRC, and this was also observedvivo by co-staining primary CRC samples for miR-224 and
spases. This was already evident in a series of preinvasive lesions
.e., LG-IEN) supporting a strong pathogenetic role for caspase
wnregulation by miR-224 during colon mucosa carcinogenesis.
A low miR-224 coupled with high caspases expression was
served in 7/10 BRAF-mutated/MMRd samples. According to
is information, data produced within the Consensus Molecular
btype (CMS) of CRC [3] showed a significant caspase activation
iocarta) in the CMS1 group which is characterized by the BRAF-
utated/MMRd status in comparison to the other three CMS
oups. These tumors are characterized by good overall and disease-
ee survivals but show the worst survival in relapsing disease after
juvant chemotherapies. Of note, a high caspase-3 activity has
en significantly correlated with a higher risk of recurrence and has
en preferentially found in tumors of the right side of the colon
(w
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Figure 5. Caspases are significantly downregulated in CRC. (A) In the TCGA CRC series, miR-224 resulted significantly upregulated in CRCs in
comparison tonormal samples (P = .001688),whereasboth caspaseswere significantly downregulated (caspase-3,P = 6.67e-08; caspase-7,
P b 2.2e-16). (B) Caspase-3 expression was significantly downregulated in CRC in comparison to normal mucosa in 4 out of 6 Oncomine
deposited studies (a total of 269 CRCs and 107 normal samples analyzed; P = .010). (C) Caspase-7was significantly downregulated in 7 out of
8 studies (a total of 415 CRCs and 186 normal samples analyzed; P = 1.02e-5).
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dings support the miR-224/caspases axis as an interesting field of
udy for innovative biomarkers/therapeutics for BRAF-mutated/
MRd tumors.Further data on the correlation between BRAF status, MMR
ficiency, and metastatic disease would be of paramount importance
the near future given the specific targeted option currently under
vestigation for these special subgroups of CRC [37–39].
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